Research Reports | Market Assessment
December 2017

Bladder Cancer | Unmet Need | US/EU | UNNEON0011-2017

Treatment of unresectable locally advanced or metastatic bladder cancer has remained relatively unchanged since the early 1990s; chemotherapy regimens are still the mainstay of treatment. However, following the 2016-2017 FDA approvals of the PD-L1 inhibitor Tecentriq (Roche/Genentech) and the PD-1 inhibitor Opdivo (Bristol-Myers Squibb) for platinum-treated patients (i.e., second and later lines), immune checkpoint inhibitors are revolutionizing the treatment algorithm for this indication.

Questions Answered:

  • What are the treatment drivers and goals for unresectable locally advanced or metastatic bladder cancer?
  • What attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for unresectable locally advanced or metastatic bladder cancer?
  • What are the prevailing areas of unmet need and opportunity in unresectable locally advanced or metastatic bladder cancer?
  • What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical new drug for unresectable locally advanced or metastatic bladder cancer?

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in January 2017

Key companies: Bristol-Myers Squibb, Eli Lilly, Roche/Genentech

Key drugs: Tecentriq, Javlor, gemcitabine

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports